Recent evidence suggests that astrocytes play an important role in regulating de-and remyelination in multiple sclerosis. The role of astrocytes is controversial, and both beneficial as well as detrimental effects are being discussed. We performed loss-of-function studies based on astrocyte depletion in a cuprizone-induced rodent model of demyelination. This led to strong astrogliosis accompanied by microgliosis and demyelination in C57BL/6 wild-type mice. Ablation of astrocytes in glial fibrillary acidic protein-thymidine kinase transgenic mice was associated with a failure of damaged myelin removal and a consecutive delay in remyelination. Despite oligodendrocyte death, myelin was still present, but ultrastructual investigations showed that the myelin structure was loosened and this damaged myelin did not protect axons. These alterations were associated with a decrease in microglial activation. Thus, our results show that astrocyte loss does not prevent myelin damage, but clearance of damaged myelin through recruitment of microglia is impaired. Further studies suggest that this process is regulated by the chemokine CXCL10. As a consequence of the delayed removal of myelin debris, remyelination and oligodendrocyte precursor cell proliferation were impaired. Experiments omitting the influence of myelin debris demonstrated an additional beneficial effect of astrocytes on oligodendrocyte regeneration during remyelination. In conclusion, these data demonstrate for the first time in vivo that astrocytes provide the signal environment that forms the basis for the recruitment of microglia to clear myelin debris, a process required for subsequent repair mechanisms. This is of great importance to understanding regenerative processes in demyelinating diseases such as multiple sclerosis.
Introduction
Multiple sclerosis is a chronic inflammatory disease of the CNS that leads to demyelination of white and grey matter (Kieseier and Stuve, 2011; Stadelmann et al., 2011) . Remyelination is the natural regenerative mechanism of demyelination, and it is proposed that remyelinated axons are protected from degeneration (Franklin and Kotter, 2008) . Unfortunately remyelination is highly variable in patients with multiple sclerosis, and for reasons not well understood, remyelination often fails or is incomplete.
Although new aspects of underlying pathomechanisms leading to de-and remyelination are being discovered continuously, the complex biological interactions are far from being completely understood. Recent evidence suggests that astrocytes may play a key role in regulating demyelinating CNS diseases (Nair et al., 2008) . Reactive astrocytosis is a prominent feature in inflammatory CNS conditions that occur in multiple sclerosis and experimental autoimmune encephalomyelitis (EAE), an inflammation-driven animal model of CNS demyelination (Eng and Ghirnikar, 1994; Bannerman et al., 2007; Guo et al., 2011) . Apart from the typical morphology with star-like projections, astrocytes are distinguished by their expression of the intermediate glial fibrillary acidic protein (GFAP). On activation, astrocytes upregulate the expression of GFAP in a process called gliosis (Eng, 1985) .
The role of astrocytes in demyelinating diseases is controversial, and both protective as well as deleterious effects on demyelination are being discussed (Williams et al., 2007; De Keyser et al., 2010; Moore et al., 2011) . Astrocytes are suggested to exert detrimental effects and promote demyelination by enhancing the immune response through expression of cytokines and recruitment of T cells, microglia and macrophages to demyelinating lesions. As astrocytes are the main producers of chemokines in multiple sclerosis, it was suggested that chemokine secretion may be the primary way in which astrocytes perpetuate immune-mediated demyelination.
In contrast, favourable effects of astrocytes on demyelination have also been proposed. The formation of a glial scar is supposed to be a physical barrier against inflammatory cells entering demyelinated areas (Nair et al., 2008) . Accordingly, in transgenic mice, ablation of proliferating astrocytes in EAE disrupts the formation of the glial scar and is associated with increased recruitment of inflammatory cells, including T cells, neutrophils and macrophages, into the CNS (Voskuhl et al., 2009) . In consequence, the exacerbated inflammation is associated with a more severe and rapidly fulminant clinical course of EAE. Astrocytes may also attenuate the inflammatory response through the production of antiinflammatory cytokines, such as interleukin 10, transforming growth factor-b and interleukin 27 (Nair et al., 2008) .
Because many of these studies were performed under in vitro conditions, our experiments aimed to give new insights into the role of astrocytes in an in vivo model of experimental demyelination. We performed detailed loss-of-function studies based on astrocyte depletion and used a well-characterized rodent model of cuprizone-induced demyelination. This rather robust model allows analysis of demyelination in the white and grey matter of the CNS, which is accompanied by a strong astrogliosis, without the interference of the peripheral immune system (Matsushima and Morell, 2001; Kipp et al., 2009; Skripuletz et al., 2011a) .
Materials and methods

Animals
To ablate reactive astrocytes selectively, GFAP-thymidine kinase transgenic mouse line 7.1 (The Jackson Laboratory) was used, in which thymidine kinase from the herpes simplex virus is targeted to astrocytes using the mouse GFAP promoter (Bush et al., 1998) . GFAPthymidine kinase transgenic mice were obtained by mating heterozygous female mice of GFAP-thymidine kinase line 7.1 with wild-type C57BL/6 male mice. GFAP-thymidine kinase mice develop normally, exhibit no changes of brain structure and are indistinguishable from wild-type littermates (Myer et al., 2006) .
Mice were genotyped by PCR for herpes simplex virus thymidine kinase. Animals underwent routine cage maintenance once a week and were microbiologically monitored according to the Federation of European Laboratory Animal Science Association's recommendations (Rehbinder et al., 1996) . Food and water were available ad libitum. All research and animal care procedures were approved by the review board for the care of animal subjects of the district government (Lower Saxony, Germany) and performed according to international guidelines on the use of laboratory animals.
Treatment of GFAP-thymidine kinase mice with ganciclovir selectively and specifically ablates astrocytes expressing GFAP-thymidine kinase through a non-inflammatory apoptotic mechanism both in vivo and in vitro (Bush et al., 1998 (Bush et al., , 1999 . Ganciclovir is a nucleoside analogue that is phosphorylated by herpes simplex virus thymidine kinase within GFAP-positive cells. Phosphorylated ganciclovir competes with endogenous nucleotide triphosphates and disrupts DNA synthesis, thereby triggering apoptotic cell death of proliferating cells. The efficacy and specificity of this ablation of proliferating astrocytes have been shown and confirmed in a number of studies (Bush et al., 1999; Faulkner et al., 2004; Voskuhl et al., 2009 ).
Induction of experimental demyelination
Experimental demyelination was induced by feeding 8-week-old male GFAP-thymidine kinase transgenic mice and wild-type C57BL/6 mice a diet containing 0.2% cuprizone (bis-cyclohexanone oxaldihydrazone, Sigma-Aldrich) mixed into a ground standard rodent chow (Skripuletz et al., 2011a) . The cuprizone diet was maintained for 5 weeks.
To investigate the effect of astrocyte ablation on demyelination, cuprizone-fed GFAP-thymidine kinase transgenic mice were treated with ganciclovir (25 mg/kg in 200 ml of PBS) intraperitoneally every day, beginning on the day of cuprizone feeding until termination of the experiment (for experimental design, see Supplementary Fig. 1A ). This ganciclovir injection protocol was identified as sufficient to cause ablation of 60-70% of astrocytes in transgenic mice. Control GFAPthymidine kinase transgenic mice were fed with cuprizone and were injected with PBS only. Control wild-type C57BL/6 mice were fed with cuprizone and were treated intraperitoneally with ganciclovir or PBS. Additional control models included GFAP-thymidine kinase transgenic mice fed with normal chow and injected with ganciclovir or PBS and C57BL/6 mice injected with PBS.
At different time points (3, 4 and 5 weeks), mice were perfused with 4% paraformaldehyde in phosphate buffer through the left cardiac ventricle as previously described (Gudi et al., 2009) . The brains were removed, postfixed in 4% paraformaldehyde and paraffin embedded. For light microscopy, 7-mm serial paraffin sections were cut and dried at 37 C overnight. Sections between bregma À 0.82 mm and bregma À1.82 mm according to the mouse atlas by Paxinos and Franklin (2001) were analysed. For PCR analysis, mice were perfused with ice-cold PBS through the left cardiac ventricle to clear blood cells from the intravascular compartment. The brains were removed and stored in ice-cold Hanks' balanced salt solution (Sigma-Aldrich) containing 15 mM N-2-Hydroxyethylpiperazine-N 0 -2-ethanesulfonic acid (HEPES) buffer and 5% glucose. Corpus callosum and cerebral cortex were dissected from whole brains under a light microscope. For immunohistochemistry, a group of six animals was investigated at all time points, whereas three animals were investigated for PCR or electron microscopic analyses, respectively.
To investigate further the effect of late astrocyte ablation on demyelination, two different injection protocols were used (for experimental design, see Supplementary Fig. 1B ). In one experimental setting, ganciclovir or PBS injections were started after Week 3 of cuprizone treatment (start of microglial infiltration and demyelination), whereas in the second experimental setting, injections were given after Week 4 (time of the peak of microglial infiltration and severe demyelination). Cuprizone-fed GFAP-thymidine kinase transgenic mice were injected with a higher dose of ganciclovir at first injection, with the aim of inducing sufficient loss of astrocytes [200 mg (in 200 ml of PBS) ganciclovir per kg]. Thereafter, ganciclovir was given every day until termination of the experiment at a dose of 25 mg (in 200 ml of PBS) of ganciclovir per kg as described earlier in the text. For each experimental setting, control GFAP-thymidine kinase transgenic mice were fed with cuprizone and were injected with PBS only. Control wild-type C57BL/6 mice were fed with cuprizone and were treated with ganciclovir or PBS as described earlier in the text. A group size of six animals was analysed at Week 5, the time point of complete demyelination of the corpus callosum. For immunohistochemistry, mice were perfused with 4% paraformaldehyde in phosphate buffer through the left cardiac ventricle, and brains were removed as described earlier.
To analyse the long-term effects of astrocyte ablation on demyelination, the cuprizone diet was maintained for 6 weeks. Cuprizonefed GFAP-thymidine kinase transgenic mice received ganciclovir (25 mg/kg in 200 ml of PBS) intraperitoneally every day, beginning on the day of cuprizone feeding until termination of the experiment (for experimental design, see Supplementary Fig. 1C ). The control groups included (i) GFAP-thymidine kinase transgenic mice fed with cuprizone and injected with PBS; (ii) wild-type C57BL/6 mice fed with cuprizone and injected with ganciclovir or PBS; (iii) GFAP-thymidine kinase transgenic mice fed with normal chow and injected with ganciclovir or PBS and (iv) C57BL/6 mice injected with PBS. For immunohistochemistry, a group size of six animals was investigated.
To investigate the effect of astrocyte ablation on remyelination, the cuprizone diet was withdrawn after 5 weeks, and mice were fed with normal food to allow remyelination (for experimental design, see Supplementary Fig. 1D ). Ganciclovir or PBS injections were started after Week 4 of cuprizone treatment. At first injection, ganciclovir was given at a dose of 200 mg/kg in 200 ml of PBS. Thereafter, ganciclovir was given every day until termination of the experiment at a dose of 25 mg/kg in 200 ml of PBS. Control GFAP-thymidine kinase transgenic mice were fed with cuprizone and were injected with PBS, and control wild-type C57BL/6 mice were fed with cuprizone and were treated with ganciclovir or PBS, as described earlier in the text. A group size of six animals was analysed.
Histology, immunohistochemistry and electron microscopy
Histology and immunohistochemistry were performed as described previously (Gudi et al., 2009; Skripuletz et al., 2010a For electron microscopy, Epon embedding was performed as previously described . See Supplementary material for details.
Quantification of glial reactions
Quantification of glial cells was performed for astrocytes (GFAP, vimentin) , proliferating astrocytes (double staining for Ki-67/GFAP), mature oligodendrocytes (Nogo-A, APC) and activated microglia (RCA-1, Mac-3). Immunopositive cells and non-nucleus-associated APP and synaptophysin-positive axons in the corpus callosum were counted in the central part in an area of at least 0.185 mm 2 using a magnification of Â 400. In the cerebral cortex, counting of immunopositive cells with identifiable nuclei [counterstaining with Mayer's haemalum solution for immunohistochemistry and 4 0 ,6-diamidino-2-phenylindole (DAPI) for immunofluorescence] was performed for the cell layers 1-6 in both left and right hemispheres at least within an area of 1.125 mm 2 using a magnification of Â 400 (Olympus BX61) as previously described (Gudi et al., 2009) . Counted cells are expressed as number of cells/mm 2 .
Determination of de-and remyelination
The extent of demyelination in the corpus callosum and cerebral cortex was analysed as described previously (Skripuletz et al., 2008 (Skripuletz et al., , 2010b . For determination of demyelination in the corpus callosum, sections stained with Luxol fast blue, myelin proteolipid protein, myelinassociated glycoprotein and myelin oligodendrocyte glycoprotein were scored in a blinded manner by three observers and graded on a scale from 0 (complete demyelination) to 3 (normal myelin). In addition to white matter demyelination, the complete cortex was subsequently analysed by light microscopy (Olympus BX61), and myelin proteolipid protein-and myelin-associated glycoprotein-stained sections were scored by three blinded observers using a scale from 0 (complete demyelination) to 4 (normal myelin) as previously described.
RNA isolation and real-time quantitative reverse transcription polymerase chain reaction
Corpus callosum was dissected from whole brains under a light microscope. Total RNA was then extracted from the tissue using the RNeasy Õ Mini Kit (Qiagen) as previously described (Gudi et al., 2011; Skripuletz et al., 2011b Cell culture and enzyme-linked immunosorbent assay for measurement of CXCL10
Primary astrocyte cultures were prepared from 1-to 3-day-old Wistar rat cortices (Janvier) as previously described (Kipp et al., 2008; Braun et al., 2009) . Twenty-four hours before astrocyte treatment, cultures were serum-deprived in Dulbecco's modified Eagle's medium containing 0.1% foetal calf serum. Cultures were treated with lipopolysaccharide (100 ng/ml, Sigma-Aldrich), tumour necrosis factor-(100 ng/ml, Invitrogen), interferon-(100 U/ml, Peprotech), glutamate (4 mM, Sigma-Aldrich) or H 2 O 2 (200 mM, Roth) for 24 h in Dulbecco's modified Eagle's medium without foetal calf serum. Previous studies revealed that the applied concentrations are sufficient to activate astrocytes, but are not toxic in the applied concentrations (Braun et al., 2009) . CXCL10 protein levels were determined in the cell culture supernatant using a commercially available rat CXCL10 ELISA development kit (Peprotech) following the manufacturer's instructions. Protein content of cell pellets was quantified using the Bicinchoninic acid (BCA) Protein Assay Reagent Kit (Thermo Scientific) following the manufacturer's protocol.
Statistical analysis
Statistical analysis was performed using ANOVA followed by the Fisher's protected least significant difference test for post hoc comparison if appropriate. All data are given as arithmetic means AE standard error of the mean (SEM). P-values of the different ANOVAs are given in the results, and group comparisons derived from post hoc analysis are provided in the figures. In the latter case, significant effects are indicated by asterisks (*P 5 0.05, **P 5 0.01, ***P 5 0.001).
Results
Astrocyte ablation during cuprizoneinduced demyelination
The degree of astrogliosis during cuprizone-induced demyelination was analysed by GFAP immunostaining. Between wild-type C57BL/6 mice and GFAP-thymidine kinase transgenic mice fed with normal chow and injected with PBS or ganciclovir, no difference could be observed in the corpus callosum ( Fig. 1 ) and cortex ( Supplementary Fig. 2 ). These results indicate that ganciclovir treatment does not change astrogliosis in non-diseased mice brains.
During cuprizone feeding, there was a marked increase in GFAP-positive astrocytes in the corpus callosum ( Fig. 1 ) and cortex ( Supplementary Fig. 2 ) after only 3 weeks of treatment that remained at a high level after 4 and 5 weeks. In cuprizonefed mice, no difference was visible between PBS-treated GFAPthymidine kinase transgenic mice and wild-type C57BL/6 mice injected with PBS or ganciclovir. After injections of ganciclovir in cuprizone-fed GFAP-thymidine kinase transgenic mice, there was a strong loss of GFAP-positive astrocytes in both the corpus callosum and cortex (for both, P 5 0.0001).
The extent of proliferating astrocytes was visualized by double staining for the marker Ki-67. In the corpus callosum, no or only few proliferating astrocytes were found in mice fed with normal chow and injected with PBS or ganciclovir ( Fig. 1) . During cuprizone treatment, the amount of proliferating astrocytes increased in PBS-treated GFAP-thymidine kinase transgenic mice and wild-type C57BL/6 mice injected with PBS or ganciclovir in a similar manner. In cuprizone-fed GFAP-thymidine kinase transgenic mice that were injected with ganciclovir, there was a strong loss of proliferating GFAP-positive astrocytes in the corpus callosum (P 5 0.0001).
In the cerebral cortex, the amount of proliferating astrocytes was lower by a factor of $25 as compared with the corpus callosum, which is in line with previous observations (Gudi et al., 2009) . No differences between the groups were found (data not shown).
To confirm the degree of astrogliosis on cuprizone treatment and the loss of astrocytes in GFAP-thymidine kinase transgenic mice after ganciclovir treatment, additional immunostaining for the marker vimentin was performed. Double staining for the markers vimentin and GFAP showed that astrocytes express both markers in cuprizone-induced demyelination (for corpus callosum, representative images from Week 3 are shown in Fig. 2 ). Double staining for the markers vimentin and RCA-1 revealed that activated microglia do not express vimentin (Fig. 2) .
Similar to the GFAP results, there was an increase in vimentinpositive astrocytes in the corpus callosum (Supplementary Fig. 3 ; P 5 0.0001) and cortex (Supplementary Fig. 3 ; P 5 0.0001) during demyelination. Ganciclovir injections in cuprizone-fed GFAPthymidine kinase transgenic mice induced a strong loss of vimentin-positive astrocytes in both areas analysed and confirmed the results of GFAP staining. In the corpus callosum, the amount of vimentin-positive proliferating astrocytes increased in the three Figure 1 Astrocytes during cuprizone treatment in the corpus callosum. In the sketch of the mouse brain (A), the boxed area represents the area of the corpus callosum that was analysed. Graphs represent mean cell numbers from six animals per time point and group of GFAP-positive astrocytes in the corpus callosum (B) and GFAP/Ki-67 double-positive proliferating astrocytes in the corpus callosum (D). Significant effects between cuprizone groups are indicated by asterisks (***P 5 0.001). In (C), representative brain sections stained for GFAP and Ki-67 are shown in the corpus callosum at Week 3 (nuclei were counterstained with DAPI). Each bar represents the mean AE SEM. GCV = ganciclovir; TG = GFAP-thymidine kinase transgenic mice; WT = wild-type mice.
cuprizone control groups (GFAP-thymidine kinase transgenic mice injected with PBS and wild-type C57BL/6 mice injected with PBS or ganciclovir), whereas a strong loss occurred after ganciclovir injections in GFAP-thymidine kinase transgenic mice (Supplementary Fig. 3 ; P 5 0.0001). Again, in the cerebral cortex, the proliferation rate of astrocytes was very low (only 0.5-2 cells/mm 2 were found), and thus no differences between the groups could be found (representative images in Supplementary Fig. 3D show the low proliferation activity of astrocytes in the cortex).
Astrocyte ablation inhibits cuprizone-induced loss of myelin
To evaluate whether astrocyte ablation affects toxin-induced demyelination, brain sections were analysed for the myelin markers myelin proteolipid protein, myelin oligodendrocyte glycoprotein and myelin-associated glycoprotein and the histochemical Luxol fast blue staining. Transgenic and wild-type mice fed with normal food and injected with PBS or ganciclovir showed normal myelin patterns in the corpus callosum ( Fig. 3 and Supplementary  Fig. 4 ) and cortex ( Supplementary Fig. 5 ).
After 3 weeks of cuprizone feeding, loss of myelin began in the corpus callosum, as shown by myelin proteolipid protein ( Fig. 3 ; P 5 0.0001), myelin-associated glycoprotein (Supplementary Fig. 4 ; P 5 0.0001), myelin oligodendrocyte glycoprotein (Supplementary Fig. 4 ; P 5 0.0001) and Luxol fast blue staining (Supplementary Fig. 4 ; P 5 0.0001). Demyelination continued during cuprizone administration and reached its maximal degradation after 5 weeks. No difference was found between wild-type C57BL/6 mice injected with PBS or ganciclovir and GFAP-thymidine kinase transgenic mice injected with PBS. Interestingly, in astrocyte-ablated GFAP-thymidine kinase transgenic mice, no or only slight demyelination was observed after 3 weeks of cuprizone treatment. At all time points investigated, demyelination was significantly diminished in GFAP-thymidine kinase transgenic mice after astrocyte ablation compared with the three cuprizone control groups.
In the cerebral cortex, similar results were found when compared with the corpus callosum. In ganciclovir-treated GFAP-thymidine kinase transgenic mice, there was a significantly reduced demyelination of the cerebral cortex after 3, 4 and 5 weeks for myelin proteolipid protein (Supplementary Fig. 5 ; P 5 0.0001) and myelin-associated glycoprotein (Supplementary Fig. 5 ; P 5 0.0001) staining compared with the three cuprizone control groups (GFAP-thymidine kinase transgenic mice injected with PBS and wild-type C57BL/6 mice injected with PBS or ganciclovir). Brain sections stained with Luxol fast blue and myelin oligodendrocyte glycoprotein were not investigated for cortical demyelination because of the low sensitivity of Luxol fast blue and myelin oligodendrocyte glycoprotein to demonstrate cortical myelin (Skripuletz et al., 2008; Gudi et al., 2009 ).
Astrocyte ablation does not change cuprizone-induced loss of oligodendrocytes
Mature oligodendrocytes were visualized using immunohistochemical staining for Nogo-A and APC. No effects on oligodendrocyte numbers were found in GFAP-thymidine kinase transgenic mice and wild-type C57BL/6 mice fed with normal chow and injected with PBS or ganciclovir in both the corpus callosum and cortex ( Fig. 4 and Supplementary Fig. 6 ).
In the corpus callosum, a severe loss of mature oligodendrocytes was detectable after cuprizone feeding. Nogo-A- (Fig. 4) and APC-positive ( Supplementary Fig. 6 ) oligodendrocytes were nearly completely depleted in all cuprizone-fed mice (GFAP-thymidine kinase transgenic mice and wild-type C57BL/6 mice injected with PBS or ganciclovir) after 3 and 4 weeks of treatment. This result is of particular interest, as it does not show any difference between the transgenic and wild-type mice, implicating that loss of astrocytes does not prevent cuprizone-induced damage/ loss of mature oligodendrocytes.
In accordance with previous results, oligodendrocytes began to reappear at Week 5 (Skripuletz et al., 2011b) . The density of newly generated Nogo-A- (Fig. 4) and APC-positive (Supplementary Fig. 6 ) cells was significantly lower in GFAP-thymidine kinase transgenic mice treated with ganciclovir as compared with PBStreated GFAP-thymidine kinase transgenic mice and wild-type C57BL/6 mice injected with PBS or ganciclovir.
Similar to the corpus callosum, a severe loss of mature oligodendrocytes occurred in the cerebral cortex after animals were fed cuprizone. Nogo-A-and APC-positive ( Supplementary Fig. 6 ) oligodendrocytes were almost completely depleted during demyelination at Weeks 3, 4 and 5 in all cuprizone-fed mice (GFAPthymidine kinase transgenic mice injected with PBS and wild-type C57BL/6 mice injected with PBS or ganciclovir). In previous studies, we demonstrated that new oligodendrocytes reappear not earlier than at Week 6 in the cortex (Skripuletz et al., 2011b) . Analogous to the corpus callosum, astrocyte ablation in GFAPthymidine kinase transgenic mice did not influence cuprizoneinduced loss of mature oligodendrocytes in the cortex.
In the cuprizone model, oligodendrocyte death and downregulation of myelin genes are already present 3-7 days after the start of cuprizone treatment and weeks before demyelination is visible in the corpus callosum (Morell et al., 1998; Komoly, 2005; Hesse et al., 2010) . We confirmed these observations by additional immunohistochemical double stainings for oligodendroglia (Nogo-A, APC) and myelin markers (myelin basic protein, myelinassociated glycoprotein, CNPase). After 3 weeks of cuprizone exposure, mature oligodendrocytes had nearly completely disappeared despite remaining myelin protein expression as shown by myelin basic protein, myelin-associated glycoprotein and CNPase stainings (Fig. 5) . Furthermore, in all cuprizone groups, including astrocyte-ablated animals, there was a marked deficiency of interfascicular oligodendrocytes in the corpus callosum as shown by haematoxylin and eosin staining (Fig. 5) . In the corpus callosum of normal-fed animals, interfascicular oligodendrocytes were found lying in rows side by side amongst the white matter nerve fibres. The loss of interfascicular oligodendrocytes in all cuprizone-fed groups confirms the immunohistochemical stainings for mature oligodendrocytes and shows that astrocyte ablation does not protect from oligodendroglial cell death in our model.
Astrocyte loss-induced preservation of myelin does not protect from axonal damage
To evaluate whether the remaining myelin after astrocyte ablation affects axons, brain sections were analysed to detect axonal damage.
First, axonal damage was analysed by quantification of APPpositive axons in the corpus callosum after 5 weeks of cuprizone exposure, the time point of maximal myelin degradation in cuprizone control mice (wild-type C57BL/6 mice injected with PBS or ganciclovir and GFAP-thymidine kinase transgenic mice injected with PBS) and the time point of preserved myelin in astrocyteablated GFAP-thymidine kinase transgenic mice. As shown in Fig. 6 , the amount of APP-positive axons was increased after 5 weeks of cuprizone exposure. No difference was found between cuprizone groups, indicating that the remaining myelin in astrocyte-ablated animals did not protect from axonal damage.
Second, staining for synaptophysin was performed to analyse axonal damage. Synaptophysin, a major synaptic vesicle membrane protein, is transported along the axon in an anterograde manner comparable with APP transport (Koo et al., 1990; Okada et al., 1995) . Axonal transport disturbances and axon transection lead to accumulation of synaptophysin in spheroid formations similar to the typical axonal swelling as shown by APP staining (Katsuse et al., 2003; Creed et al., 2011; Schirmer et al., 2012) . In our study, synaptophysin-positive axons were found in the corpus callosum after 5 weeks of cuprizone feeding (Fig. 6) . The results confirmed those found in the APP staining, as no difference was found for axonal damage between cuprizone groups.
Additional double stainings for APP and the myelin marker proteolipid protein, and synaptophysin and proteolipid protein, show axonal damage despite preserved myelin (Fig. 6C) . These results indicate that the function of myelin is lost in astrocyte-ablated animals. Figure 4 Mature oligodendrocytes during cuprizone treatment in the corpus callosum and cerebral cortex. Graphs represent mean cell numbers per time point and group of Nogo-A-positive oligodendrocytes in the corpus callosum (A) and cortex (C). Significant effects between cuprizone groups are indicated by asterisks (*P 5 0.05, **P 5 0.01, ***P 5 0.001). In (B), representative brain sections stained for Nogo-A are shown in the corpus callosum at Week 3 (nuclei were counterstained with DAPI). Each bar represents the mean AE SEM. GCV = ganciclovir; TG = GFAP-thymidine kinase transgenic mice; WT = wild-type mice. Figure 5 Haematoxylin and eosin stain (H&E) was performed to present interfascicular oligodendrocytes in normal-fed control mice.
During cuprizone treatment, there was a marked deficiency of interfascicular oligodendrocytes in all cuprizone groups, including astrocyte-ablated animals, in the corpus callosum. In the figure, representative stained brain sections are shown in the corpus callosum at Week 3 (nuclei were counterstained with DAPI). Additional immunohistochemical double stainings for oligodendroglial marker and myelin marker (Nogo-A/myelin basic protein, Nogo-A/myelin-associated glycoprotein, Nogo-A/CNPase, APC/myelin-associated glycoprotein, APC/CNPase) were performed. After 3 weeks of cuprizone exposure, mature oligodendrocytes have nearly completely disappeared despite remaining myelin protein expression as shown by myelin basic protein, myelin-associated glycoprotein and CNPase stainings. GCV = ganciclovir; TG = GFAP-thymidine kinase transgenic mice; WT = wild-type mice. Figure 6 Axonal damage occurs despite preserved myelin at Week 5 of cuprizone feeding. Axonal damage was analysed by immunohistochemical stainings for APP and synaptophysin. Graphs represent mean cell numbers AE SEM per group of (A) APP-and (B) synaptophysin-positive axons in the corpus callosum. In (C), representative brain sections stained for APP and synaptophysin are shown in the corpus callosum at Week 5 (nuclei were counterstained with Mayer's haemalum solution). Double stainings for APP and proteolipid protein as well as synaptophysin and proteolipid protein show axonal damage despite preserved myelin (C). Ultrastructural analyses were performed to show myelinated axons in the corpus callosum. Representative brain sections are shown in the corpus callosum of control wild-type C57BL/6 mice fed with normal chow (D1 and D2) and of cuprizone-fed mice at Week 5 (D3 and D4: wild-type C57BL/6 mice injected with PBS; D5-7: GFAP-thymidine kinase transgenic mice after astrocyte ablation). Wild-type mice show nearly complete demyelination (D3 and D4), whereas after astrocyte ablation, many axons remained myelinated (D5-7). The myelinated axons present disturbed myelin structure such as splits, sheath breakdown and vacuolated formations. GCV = ganciclovir; TG = GFAP-thymidine kinase transgenic mice; WT = wild-type mice.
Astrocyte ablation does not prevent myelin damage but inhibits the clearance of myelin debris
The discrepancy between preserved myelin despite oligodendrocyte and axonal damage led to electron microscopy studies to evaluate whether astrocyte loss affects myelin integrity on the ultrastructural level.
The three cuprizone groups with extensive reactive astrogliosis (wild-type C57BL/6 mice injected with PBS or ganciclovir and GFAP-thymidine kinase transgenic mice injected with PBS) showed nearly complete demyelination of axons after 5 weeks of cuprizone feeding (only 0-3% of axons remained myelinated; Fig. 6D ). In contrast, after ablation of astrocytes in the GFAPthymidine kinase transgenic mice, many axons remained myelinated (31-42% of axons remained myelinated; Fig. 6D ). However, the majority of myelin sheaths presented an altered myelin structure. The circumferential outlines of these myelin lamellae were irregular. The myelin sheaths displayed splits, sheath breakdown and vacuolated formations. These ultrastructural examinations revealed that myelin damage did occur in astrocyte-depleted brains of GFAP-thymidine kinase transgenic mice, but without clearance of the altered myelin.
Recruitment of microglia is decreased after astrocyte loss
Accumulation of activated microglia was investigated by RCA-1 and Mac-3 stainings. The whole population of microglia was investigated with the marker Iba-1, which also stains resting microglia. No activated microglia were found in transgenic and wild-type mice fed with normal chow and injected with PBS or ganciclovir, either in the corpus callosum (Fig. 7) or in the cortex (Supplementary Fig. 7 ). Iba-1-positive microglia were found in mice fed with normal chow, but no difference between the groups could be observed ( Supplementary Fig. 8 ).
In the corpus callosum and cortex, numbers of RCA-1-( Fig. 7  and Supplementary Fig. 7 ; for both, P 5 0.0001), Mac-3-(data not shown; for both, P 5 0.0001) and Iba-1-positive (Supplementary Fig. 8 ; for both, P 5 0.0001) microglia increased strongly after 3 weeks of cuprizone treatment and reached a peak after 4 weeks in wild-type animals, whereupon a decrease occurred. No difference was found between wild-type C57BL/6 mice injected with PBS or ganciclovir and GFAP-thymidine kinase transgenic mice injected with PBS.
However, when GFAP-thymidine kinase transgenic mice were treated with ganciclovir, numbers of RCA-1-, Mac-3-and Iba-1-positive microglia were significantly decreased compared with the three cuprizone control groups after Weeks 3, 4 and 5 in both the corpus callosum and cortex.
To determine the activation state of microglia during demyelination, brain sections stained with Luxol fast blue/periodic acidSchiff were analysed. Periodic acid-Schiff-positive material in microglia is well described as an indicator of myelin phagocytosis (Bitsch et al., 2000; Lin et al., 2005; Skripuletz et al., 2008; Kondo et al., 2011) . In the corpus callosum and cortex, accumulation of periodic acid-Schiff-positive microglia began after 3 weeks of cuprizone diet and peaked after 4 weeks, similar to the RCA-1, Mac-3, and Iba-1 staining. In astrocyte-ablated GFAP-thymidine kinase transgenic mice, microglia containing periodic acid-Schiffpositive products of myelin degradation were also found, indicating that despite astrocyte loss, microglia were able to phagocytose (representative images are shown in Supplementary Fig. 9) . Thus, the decreased myelin debris removal is rather the result of the reduced microglia recruitment into the lesion.
Effect of astrocyte ablation correlates with microglia activation
In two additional experimental settings, ganciclovir treatment was started at Week 3 (beginning of microglial recruitment and demyelination) or Week 4 (peak of microglial recruitment and presence of strong demyelination).
When ganciclovir treatment was started at Week 3 of cuprizone treatment, demyelination in the corpus callosum and cortex was significantly diminished compared with the three cuprizone control groups, as shown by proteolipid protein staining at Week 5 ( Fig. 8A-C ; corpus callosum, P 5 0.0001; cortex, P = 0.001). Accordingly, no differences were found between wild-type C57BL/6 mice injected with PBS or ganciclovir and GFAP-thymidine kinase transgenic mice injected with PBS.
When ganciclovir treatment was started at Week 4 of cuprizone treatment, astrocyte ablation, in turn, did not influence demyelination in the corpus callosum nor in the cortex (Fig. 8D-F) . At Week 5, complete demyelination occurred in the corpus callosum and strong demyelination occurred in the cortex in all cuprizone groups, showing no difference between groups (C57BL/6 mice injected with PBS or ganciclovir and GFAP-thymidine kinase transgenic mice injected with PBS or ganciclovir). These results indicate that astrocyte ablation at Week 4 cannot influence demyelination when microglia are already recruited and there is prominent microgliosis.
Astrocyte ablation decreases messenger RNA expression of CXCL10
To further identify factors involved in attracting microglia to demyelinating lesions, the messenger RNA expression of selected chemokines that have been associated with microglial recruitment was analysed.
After 3 weeks of cuprizone feeding when microglial recruitment started, the expression of CXCL10 was found to be strongly upregulated in wild-type C57BL/6 mice injected with PBS or ganciclovir and GFAP-thymidine kinase transgenic mice injected with PBS ( Fig. 9 ; P 5 0.001). In GFAP-thymidine kinase transgenic mice injected with ganciclovir, a significantly reduced expression of CXCL10 was found compared with the three cuprizone control groups, suggesting that astrocytes are the major source of CXCL10 messenger RNA expression in cuprizone-induced demyelination. Immunohistochemical stainings for CXCL10 were performed to confirm the cellular source of this chemokine. Indeed, the cells producing CXCL10 showed astrocytic shape, and double stainings with GFAP confirmed this (Fig. 9 ). Double stainings with the microglia marker RCA-1 showed no co-localization of CXCL10 in these cells (Fig. 9) .
To further confirm the secretion of CXCL10 in astrocytes, additional cell culture experiments were performed. In astrocytes stimulated with lipopolysaccharide, interferon-or tumour necrosis factor-, there was a significantly increased secretion of CXCL10 compared with control ones (Supplementary Fig. 10 ; P 5 0.0001). These in vitro data support the in vivo finding that astrocytes produce CXCL10.
The messenger RNA expression of CCL2 and CCL3 was found to be strongly upregulated during cuprizone-induced demyelination in all cuprizone-fed groups (C57BL/6 mice injected with PBS or ganciclovir and GFAP-thymidine kinase transgenic mice injected with PBS or ganciclovir) as compared with mice fed with normal chow (data not shown). There was no difference after astrocyte ablation, indicating that astrocytes do not play a major role in providing these chemokines in this model. CXCL12 and CXCL13 seem to have no influence in cuprizoneinduced demyelination, as no difference in the messenger RNA expression was found in transgenic and wild-type mice fed with cuprizone or fed with normal chow (data not shown).
Decreased microgliosis after astrocyte ablation delays the clearance of myelin debris
As described earlier in the text, astrocyte ablation prevented myelin clearance in the corpus callosum and cortex through the Course of demyelination in the corpus callosum and cortex during cuprizone treatment in response to late astrocyte ablation. In two experimental settings, astrocyte ablation was started at Week 3 (beginning of microglial recruitment and demyelination; A-C) or Week 4 (peak of microglial recruitment and presence of strong demyelination; D-F). The extent of demyelination was judged by scoring of proteolipid protein. Brain sections were scored in a blinded manner by three independent observers. A score of 3 represents complete myelination in the corpus callosum, and a score of 4 represents normal myelination in the cortex. A score of 0 represents complete demyelination in the corpus callosum and cortex. Significant effects between cuprizone groups are indicated by asterisks (**P 5 0.01, ***P 5 0.001). In (C) and (F), representative brain sections stained for proteolipid protein are shown in the corpus callosum at Week 5. Each bar represents the mean AE SEM. GCV = ganciclovir; TG = GFAP-thymidine kinase transgenic mice; WT = wild-type mice. reduction of microglia recruitment to the lesion. Additional analyses revealed that the remaining myelin is damaged and does not prevent axonal damage. Thus, a further time point (Week 6) was investigated to analyse what happens with the damaged myelin in the astrocyte-ablated transgenic mice.
At Week 6 of cuprizone exposure, all myelin sheaths in the corpus callosum have been cleared in astrocyte-ablated transgenic mice, whereas in control mice (wild-type C57BL/6 mice injected with PBS or ganciclovir and GFAP-thymidine kinase transgenic mice injected with PBS), there already was remyelination. As shown by proteolipid protein, Luxol fast blue, myelin-associated glycoprotein and myelin oligodendrocyte glycoprotein staining, nearly complete demyelination could be observed in astrocyte-ablated mice (Fig. 10) . Remyelination during continued cuprizone administration at Week 6 is well described (Matsushima and Morell, 2001; Gudi et al., 2009) . Only with myelin oligodendrocyte glycoprotein there was no significant difference between the groups in myelin protein re-expression, which is in accordance with previous studies and developmental myelination (first, myelin basic protein, followed by proteolipid protein and finally by myelin oligodendrocyte glycoprotein; Gudi et al., 2009) . This result indicates that the removal of damaged myelin was delayed as a consequence of astrocyte ablation, and that this process is required before remyelination can occur.
In contrast to the corpus callosum, demyelination of the cortex is delayed, and complete demyelination occurs 1 week later at the Week 6 time point in the cuprizone model (Skripuletz et al., 2008; Gudi et al., 2009) . Accordingly, we found nearly complete demyelination, as shown by myelin proteolipid protein and myelinassociated glycoprotein staining, in the three cuprizone control groups (wild-type C57BL/6 mice injected with PBS or ganciclovir and GFAP-thymidine kinase transgenic mice injected with PBS; Supplementary Fig. 13 ). Interestingly, in astrocyte-ablated transgenic mice, higher amounts of myelin proteolipid protein and myelin-associated glycoprotein were found at Week 6 compared with the three cuprizone control groups, showing that myelin clearance is also delayed in the cortex (for both P 5 0.0001).
Owing to regional differences, oligodendrocytes reappear first after Week 6 in the cortex, and thus, only low numbers of Nogo-A-and APC-positive oligodendrocytes were found in all cuprizone groups at week 6 ( Supplementary Fig. 13 ).
Analysis of glial reactions at Week 6 showed that a strong loss of GFAP-and vimentin-positive astrocytes was still observed in the corpus callosum and cortex after injections of ganciclovir in cuprizone-fed GFAP-thymidine kinase transgenic mice (Supplementary Fig. 12 and 13 ; for all, P 5 0.0001). At Week 6, microglia numbers (RCA-1-, Mac-3-and Iba-1-positive cells) decreased strongly compared with Week 5 in the corpus callosum and cortex in the cuprizone groups, and no difference between the groups was observed ( Supplementary Fig. 12 and 13 ).
Astrocyte ablation inhibits the regeneration of oligodendrocytes and myelin
The numbers of Nogo-A-and APC-positive cells in the corpus callosum after 5 and 6 weeks of cuprizone treatment indicate a decreased regeneration of oligodendrocytes after astrocyte ablation (Figs 4, 10 and Supplementary Fig. 6 ).
To further evaluate the role of astrocytes in oligodendrocyte precursor cell proliferation, double staining for Olig-2 and Ki-67 was performed. On cuprizone-induced demyelination, the numbers of proliferating oligodendrocyte precursor cells increased in Figure 9 Expression of CXCL10 (interferon-inducible protein-10) messenger RNA in the corpus callosum at Week 3. Graphs show messenger RNA expression fold changes of CXCL10 compared with wild-type normal-fed control mice. Significant effects between cuprizone groups are indicated by asterisks (*P 5 0.05). Double stainings with the markers CXCL10 and GFAP show that astrocytes express the chemokine CXCL10 in cuprizone-induced demyelination. Double stainings with the markers CXCL10 and RCA-1 show that activated microglia do not express CXCL10. Nuclei were counterstained with DAPI. Each bar represents the mean AE SEM. GCV = ganciclovir; TG = GFAP-thymidine kinase transgenic mice; WT = wild-type mice. the three cuprizone control groups (wild-type C57BL/6 mice injected with PBS or ganciclovir and GFAP-thymidine kinase transgenic mice injected with PBS) and reached a peak after 4 weeks, followed by a decline in both areas analysed (Fig. 11, Supplementary Figs 11, 12 and 13) . After astrocyte ablation in transgenic mice, the numbers of proliferating oligodendrocyte precursor cells were clearly reduced in the corpus callosum compared with the cuprizone control groups (P 5 0.0001). In the cortex, reduced numbers of proliferating oligodendrocyte precursor cells were found in the astrocyte-ablated transgenic mice at the peak of proliferation (Week 4 of cuprizone feeding; P 5 0.0001).
These results suggest that the loss of astrocytes negatively affects oligodendrocyte precursor cell proliferation and differentiation and leads to decreased remyelination. Because myelin debris is a potent inhibitor of remyelination by inhibiting oligodendrocyte precursor cell differentiation (Kotter et al., 2006) , the delayed myelin clearance in astrocyte-ablated transgenic mice might inhibit oligodendrocyte precursor cell differentiation into oligodendrocytes and thus myelin regeneration. We therefore injected transgenic mice with ganciclovir, beginning at Week 4.
As described earlier in the text, after 4 weeks of astrocyte loss, demyelination is not affected. This allowed investigation of remyelination without the inhibitory effects of remaining myelin debris. Mice were fed with cuprizone for up to 5 weeks, followed by 1 week of normal chow to allow remyelination. After 1 week on normal chow, strong remyelination was observed in the three cuprizone control groups, and no significant difference between these groups was found (Fig. 12 ). It was already described that the extent of myelin protein re-expression is extremely fast and robust in the corpus callosum in the cuprizone model (Matsushima and Morell, 2001; Lindner et al., 2008; Kipp et al., 2009; Skripuletz et al., 2011a) . In contrast, transgenic mice after astrocyte ablation showed significantly reduced amounts of new myelin as shown by Luxol fast blue and proteolipid protein stainings compared with the cuprizone control groups (P = 0.004 for Luxol fast blue, P 5 0.0001 for proteolipid protein; Fig. 12 ). Analogous to myelin re-expression, the density of Nogo-A-positive oligodendrocytes was significantly decreased in astrocyte-ablated transgenic mice compared with the three cuprizone control groups (P 5 0.001; Fig. 12 ). These results show that astrocyte Figure 10 Myelin and oligodendrocytes after 6 weeks of cuprizone feeding in the corpus callosum. Corpus callosum was analysed for different myelin and oligodendroglial markers: proteolipid protein (A), Luxol fast blue (B), myelin-associated glycoprotein (C), myelin oligodendrocyte glycoprotein (D) and, for mature oligodendrocytes, Nogo-A (E) and APC (F). Each bar represents the mean AE SEM. Significant effects between cuprizone groups are indicated by asterisks (*P 5 0.05, **P 5 0.01, ***P 5 0.001). GCV = ganciclovir; LFB = Luxol fast blue; MAG = myelin-associated glycoprotein; MOG = myelin oligodendrocyte glycoprotein; PLP = myelin proteolipid protein; TG = GFAP-thymidine kinase transgenic mice; WT = wild-type mice. loss exerts detrimental effects on remyelination via decreased numbers of oligodendrocytes.
Discussion
The aim of our study was to clarify the role of astrocytes in demyelinating diseases. We show here that astrocytes provide a signal environment that forms the basis for the recruitment of microglia and oligodendrocyte precursor cells that is required for successful remyelination.
The effects of astrocytes on CNS de-and remyelination were investigated in a well-described transgenic mouse model that enables the ablation of astrocytes as a consequence of ganciclovir treatment. This led to a loss of astrogliosis in both the grey and white matter in cuprizone-induced de-and remyelination.
Astrocytes regulate clearance of myelin debris
Interestingly, the extent of demyelination, as judged by histochemistry and immunohistochemistry, was significantly diminished in transgenic mice after astrocyte ablation as compared with the cuprizone control groups. However, reduction in mature oligodendrocyte numbers was not affected by the ablation of astrocytes, and axonal damage occurred to a similar extent in astrocyte-ablated animals as in the cuprizone control groups, indicating a loss of trophic support of the myelin. This discrepancy between oligodendrocyte and axonal damage and preserved myelin was resolved by additional ultrastructural analyses. Electron microscopy revealed that the ablation of astrocytes succeeded in higher numbers of myelinated axons; however, the structure of myelin was mostly disrupted. Thus, astrocyte ablation did not preserve myelin damage but inhibited the clearance of damaged myelin sheaths. This was associated by a reduced number of activated microglia in astrocyte-ablated transgenic mice, which alludes to a lack of microglia recruitment and phagocytosis of myelin debris.
Because the delay of myelin removal was accompanied by a distinct reduction of activated microglia in astrocyte-ablated animals, we analysed the time window of astrocyte effects on demyelination. In two different temporal injection protocols, astrocyte ablation was started at Week 3 (beginning of microglial recruitment) or Week 4 (peak of microglial recruitment). Accordingly, ablation of astrocytes at the beginning of microglial recruitment resulted in decreased myelin removal in the corpus callosum and the cortex. When astrocyte ablation was started at the peak of microglia activation, there was no effect on myelin clearance. These different injection protocols illustrate that the recruitment of microglia and myelin removal depend on the presence of astrocytes. Figure 12 Remyelination and regeneration of oligodendrocytes in the corpus callosum 1 week after cuprizone withdrawal. The extent of remyelination was judged by scoring of Luxol fast blue (LFB; A) and proteolipid protein (PLP; B). Brain sections were scored in a blinded manner by three independent observers. A score of 3 represents complete myelination, and a score of 0 represents complete demyelination. In (C), representative brain sections stained for LFB and PLP are shown in the corpus callosum at Week 6 (1 week after remyelination). (D) Graph represents the mean cell numbers per group of Nogo-A-positive oligodendrocytes in the corpus callosum. (E) Representative brain sections stained for Nogo-A are shown in the corpus callosum at Week 6 (nuclei were counterstained with DAPI). Significant effects between cuprizone groups are indicated by asterisks (**P 5 0.01, ***P 5 0.001). Each bar represents the mean AE SEM. GCV = ganciclovir; TG = GFAP-thymidine kinase transgenic mice; WT = wild-type mice.
Delayed removal of damaged myelin prevents early remyelination
When cuprizone was fed over a longer period, all myelin sheaths in the corpus callosum were cleared at Week 6 in astrocyteablated GFAP-thymidine kinase transgenic mice, indicating a delay in myelin debris clearance. While there is remyelination in wild-type mice at this time point, this was prevented in astrocyteablated transgenic mice by the delay in myelin removal. This illustrates the importance of myelin debris clearance for allowing remyelination and repair to occur. We think that this also holds true for repair processes in multiple sclerosis, where the myelin damaged by the immune response has to be cleared before remyelination can occur.
Astrocytes provide signals to attract microglia
Recruitment of activated microglia is a characteristic finding of most CNS autoimmune disorders, and both protective and detrimental functions have been proposed (Rasmussen et al., 2007; Simard and Rivest, 2007; Murphy et al., 2010) . During demyelination, microglia exhibit an activated phenotype with a high phagocytic activity (Voss et al., 2012) . Clearing damaged myelin presents an essential mechanism in demyelination, and it was shown that depletion of microglia/macrophages impaired myelin debris clearance, and thus demyelination and consequently remyelination (Kotter et al., 2006) . There is increasing evidence that myelin clearance by microglia/macrophages is required for resolution of the inflammatory response and for efficient initiation of remyelination (Neumann et al., 2009) . In particular, myelin debris was identified as an inhibitor of oligodendrocyte precursor cell differentiation (Kotter et al., 2006) . Furthermore, microglia/ macrophages containing myelin are known to contain antiinflammatory molecules while lacking proinflammatory cytokines (Boven et al., 2006) . Our data suggest that there is no clearance of disrupted myelin, a prerequisite for myelin repair when microglia are not recruited by astrocytes.
The role of astrocytes in demyelinating diseases is controversially discussed, and both protective and detrimental functions have been proposed (Nair et al., 2008; Moore et al., 2011) . It was suggested that astrocytes are required for demyelination in the CNS by secreting a variety of factors, such as the chemokines CCL2, CCL3, CXCL10 and CXCL12, to attract inflammatory cells, such as microglia and macrophages, to the lesion (Babcock et al., 2003; El Hage et al., 2006; Bianchi et al., 2011; Qin and Benveniste, 2012) . Thus, we analysed the messenger RNA expression of these chemokines in demyelinating lesions to identify astrocytic factors involved in the diminished microgliosis. Levels of CXCL10 messenger RNA expression were found to be strongly upregulated during demyelination in mice with normal astrocyte function, whereas in GFAPthymidine kinase transgenic mice after astrocyte ablation, a significantly reduced expression of CXCL10 messenger RNA was found. Double immunofluorescence stainings revealed that CXCL10 was expressed in reactive astrocytes but not in activated microglia. The secretion of CXCL10 by astrocytes could be confirmed by additional in vitro experiments and was upregulated by interferon-, tumour necrosis factor-or lipopolysaccharide.
A major role of astrocytes and CXCL10 in demyelinating diseases was already suggested by previous immunohistochemical Figure 13 Schematic overview of astrocyte-mediated myelin clearance via recruitment of activated microglia to the lesion through upregulation of the chemokine CXCL10. In (A), reactive astrocytes secrete the chemokine CXCL10, which induces migration of microglia to cuprizone-damaged myelin lesions in the attempt to phagocytose the damaged myelin. In (B), reactive astrocytes were ablated using a transgenic mouse model during cuprizone-induced demyelination. The low numbers of astrocytes lead to a lower secretion of chemokines, and thus decreased recruitment of microglia. Lower microgliosis prevents from clearing the myelin debris. Thus, our results show that astrocytes exert beneficial effects in demyelinating diseases. Astrocytes are essential for demyelination through clearing the myelin debris by influencing the recruitment of microglia to damaged lesions. analyses on brain tissue from patients with multiple sclerosis (Tanuma et al., 2006) . CXCL10 was found to be highly expressed at the rim of demyelinating plaques, and double immunofluorescence stainings showed that CXCL10 was expressed by astrocytes and not by microglia. This led to the suggestion that CXCL10 may be involved in migration and activation of microglia/ macrophages. Our results confirm these observations by showing that the expression of CXCL10 is associated with astrocytes and is decreased after their ablation.
Astrocytes create a repair-permissive environment
A beneficial function of astrocytes has also been attributed to their ability to form glial scars, which limit CNS inflammation by constituting a physical barrier for inflammatory cells to enter demyelinated areas. In the immune-mediated animal model EAE, ablation of astrocytes in GFAP-thymidine kinase transgenic mice (as in our study) resulted in a disrupted formation of the glial scar, which was associated with an increased recruitment of peripheral inflammatory cells into the CNS, including T cells, neutrophils and macrophages (Voskuhl et al., 2009) . In these mice, a more severe clinical EAE course was observed. Similar results were shown by another EAE study, in which the astrocyte-specific function of gp130 was analysed in GFAP-Cre gp130 mice (Haroon et al., 2011) . Mice lacking the cell surface expression of gp130 developed a clinically more severe EAE, accompanied by larger areas of demyelination and increased numbers of CD4 T + cells in the CNS. The results from different animal models show that astrocytes exert various parts of action in demyelination, and that it is not possible to uncover their complex pathobiology in demyelination by using only one animal model. To induce demyelination different myelin insults such as inflammation, toxins, viruses and genetic myelin mutations can be used (Schreiner et al., 2009) . Because no animal model covers the complex pathomechanisms of human multiple sclerosis, the various animal models need to be used selectively to analyse different aspects of demyelination and remyelination in the attempt to fill gaps not presented by other models. The cuprizone model is particularly suitable to investigate remyelination without the possible interferences of peripheral immune cells such as macrophages and lymphocytes (Matsushima and Morell, 2001; Kipp et al., 2009; Skripuletz et al., 2011a) . In addition to the role of astrocytes to provide the required signals to recruit microglia and thus allow the efficient removal of damaged myelin as a prerequisite for remyelination, we could demonstrate that astrocytes contribute to create a repair permissive environment during remyelination after the myelin debris has been removed. Astrocyte ablation at this time point impairs oligodendrocyte generation and formation of new myelin.
In conjunction with previous studies and our present data, we propose a dual beneficial mechanism of action for astrocytes on remyelination: regenerative effects by recruiting phagocytosing cells to clear damaged myelin, and regenerative effects by modulating the regeneration of oligodendrocyte precursor cells and thus oligodendrocytes.
Conclusion
In conclusion, we show that astrocytes are essential to activate microglia for removal of damaged myelin sheaths in vivo that impacts a subsequent remyelination. The recruitment of activated microglia seems to be mediated through CXCL10 upregulation in astrocytes (Fig. 13) . These data corroborate the hypothesis that astrocytes are one of the key regulators in demyelinating processes of the CNS, and confirm the long-postulated crosstalk between astrocytes and microglia in demyelinating lesions. We believe that this can be extended to multiple sclerosis, where, similarly, the immune-mediated myelin damage needs to be resolved before remyelination can commence. Understanding these processes is of importance to design repair promoting therapies.
